A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Latest Information Update: 08 Jul 2022
At a glance
- Drugs SRP-5051 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors Sarepta Therapeutics
- 27 Aug 2019 Status changed from recruiting to completed.
- 02 Nov 2018 Planned End Date changed from 30 Sep 2019 to 1 Sep 2019.
- 02 Nov 2018 Planned primary completion date changed from 30 Sep 2019 to 1 Sep 2019.